Mounjaro

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Lilly aims to seek approval with a potential 2026 rollout, positioning the once‑daily tablet as a more accessible alternative to injections.